Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
This study is assessing ABBV-637 and ABBV-155 with ERAS-801 or standard treatment in people with glioblastoma. The people in this study have newly diagnosed glioblastoma or glioblastoma that returned after treatment and can be surgically removed. In addition, their tumors have a mutation (change) in the EGFR gene.
Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if adding zanidatamab to standard treatment works well against biliary tract cancer. The people in this study have biliary tract cancer that has spread or cannot be removed with surgery. In addition, their cancers make a protein called HER2.
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient's healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
